UTv Videos

“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.

"What we're really trying to see now is this integration of imaging and using it with respect to AI and planning," says Dean S. Elterman, MD, MSc, FRCSC.

“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP.

"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD.

"I think this is the next step for testing the clinical activity of this agent," says David A. Braun, MD, PhD.

"We see that among the patients who went on to receiving cystectomy, 84% are metastases free," says Pooja Ghatalia, MD.

"The efficacy findings reported to date are 71% any time response," says John A. Taylor III, MD, MS.

“Both groups benefited, but it would look like earlier is better if we can treat patients with low-volume disease,” says Fred Saad, MD, FRCS

“Of the 3 adrenal androgens, it's DHEA that seems to be most indicative of overall survival,” says Nima Sharifi, MD.

"For the MIRAGE trial specifically, we're going to continue following patients and we'll look at [data at] 5 years as well," says Amar U. Kishan, MD.

"I think targeting things that make communities more vulnerable would be reasonable things to target to try and affect disease practices," says William Furuyama, MD.

“While I would hesitate to say that reversal is truly better in terms of efficacy, I think this data suggests that it's at least as good,” says Scott D. Lundy, MD, PhD, HCLD.

Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine.

"We need to promote further research and guidelines for safe use of these natural products, because I think we're missing out if we don't monitor them," says Channing J. Paller, MD.

"I want to add that the safety profile was impeccable for this. No one experienced a [device-related] adverse event," says Matthew J. Mutter, MD.

"A lot of shared decision-making has to do with, what is important to the individual man?" says Dean S. Elterman, MD, MSc, FRCSC.

"My second book is on pelvic pain or prostatitis. It is focused on a holistic approach and stretches and mindfulness exercises," says Vanita Gaglani, RPT.

“I would say both there could be an increase in MRI-guided [SBRT] and there may be increase in investigation into shrinking margins with CT-guided SBRT as well,” says Amar U. Kishan, MD.

"Despite the fact that multiple new procedures have come to light, nothing has the same excellent outcomes as HoLEP," says Amy E. Krambeck, MD.

“While sperm cryopreservation is very safe, there might be hidden costs that patients aren't aware of, both [in] the upfront costs of preserving the sperm and then the annual cost of maintaining it at a facility,” says Bradley Roth, MS4.

"It was interesting to think about the relationship between a disease process and a person's environment, and measure that and establish that relationship in a quantitative way," says William Furuyama, MD.

“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R. Cooperberg, MD, MPH.

"Most of these comorbidities, while they do affect the bladder, don't seem to affect the surgeries for stress urinary incontinence," says Jaspreet S. Sandhu, MD.

"We need to think carefully about what we're putting in our body and what the regulations are about natural products that we ingest," says Channing J. Paller, MD.

"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne Pelletier Cameron, MD, FRCSC, FPMRS.

"Physician scored GU toxicity grade 2 or greater at 2 years was 51% with the CT-guided and 27% with the MRI-guided," says Amar U. Kishan, MD.

“It does seem clear that we need to get back to a smarter middle ground of screening—using screening more intelligently, finding the high-grade cancers and treating them—so that we can get that mortality curve back on a downward trajectory,” says Matthew R. Cooperberg, MD, MPH.

"It really remains to be seen whether we can expand this to care for other types of urological inpatients," says Timothy D. Lyon, MD.

"I would say the fact that we performed 754 HoLEP procedures in 2024 is a reflection of the efficiency and the high quality of care that you receive at Northwestern," says Amy E. Krambeck, MD.

"The idea here is to determine, from an epidemiologic perspective, whether freezing sperm for many men before their vasectomy is cost-effective compared to whether we should simply avoid this routine practice and allow men to proceed with their vasectomy and then restore their fertility in the future," says Scott D. Lundy, MD, PhD, HCLD.